scholarly journals The role of direct oral anticoagulants in the treatment of cancer associated venous thromboembolism

Oncoreview ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 70-75
Author(s):  
Elizaveta Panchenko ◽  
Julia Fedotkina ◽  
Anatoly Dobrovolsky
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants

scholarly journals Use of direct oral anticoagulants for postoperative venous thromboembolism prophylaxis after surgery for gynecologic malignancies

2022 ◽  
pp. ijgc-2021-003006
Author(s):  
Marilyn Boo ◽  
Peter Sykes ◽  
Bryony Simcock
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Postoperative Mortality ◽  
Standard Of Care ◽  
Pelvic Surgery ◽  
Gynecologic Malignancies ◽  
Current Standard ◽  
Thromboembolism Prophylaxis

Venous thromboembolism is a preventable cause of postoperative mortality in patients undergoing surgery for malignancy. Current standard of care based on international guideline recommends 28 days of extended thromboprophylaxis after major abdominal and pelvic surgery for malignancies with unfractionated heparin or low molecular weight heparin. Direct oral anticoagulants have been approved for the treatment of venous thromboembolism in the general population. This regimen has a significant advantage over other types of anticoagulation regimens, particularly being administered by non-parenteral routes and without the need for laboratory monitoring. In this review, we evaluate the role of direct anticoagulation and provide an update on completed and ongoing clinical trials.

scholarly journals Venous Thromboembolism: Role of the Clinical Laboratory in Diagnosis and Management

2019 ◽  
Vol 3 (5) ◽  
pp. 870-882 ◽  
Author(s):  
Rugvedita S Parakh ◽  
Daniel E Sabath
Keyword(s):  
Venous Thromboembolism ◽  
Clinical Laboratory ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Outpatient Basis ◽  
Risk Patients ◽  
Cardiovascular Illness ◽  
Newer Anticoagulants

Abstract Background Venous thromboembolism (VTE) is the third most common cause of cardiovascular illness and is projected to double in incidence by 2050. It is a spectrum of disease that includes deep venous thrombosis (DVT) and pulmonary embolism (PE). In February 2016, the American College of Chest Physicians provided updated management guidelines for DVT and PE to address some of the unresolved questions from the previous version and to provide recommendations related to newer anticoagulants. Content Here we review current concepts for screening, diagnosis, thromboprophylaxis, and management of DVT and PE. We also describe the management of VTE in acute, long-term, and extended phases of treatment. Thrombophilia testing is rarely necessary and should be used judiciously; the laboratory can serve an important role in preventing unnecessary testing. The direct oral anticoagulants are as effective as conventional treatment and are preferred agents except in the case of cancer. The initial management of PE should be based on risk stratification including the use of D-dimer testing. Thrombolysis is used in cases of hemodynamically unstable PE and not for low-risk patients who can be treated on an outpatient basis. Summary This review is intended to provide readers with updated guidelines for screening, testing, prophylaxis, and management from various organizations.

scholarly journals Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH

2018 ◽  
Vol 16 (9) ◽  
pp. 1891-1894 ◽  
Author(s):  
A. A. Khorana ◽  
S. Noble ◽  
A. Y. Y. Lee ◽  
G. Soff ◽  
G. Meyer ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants

scholarly journals Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 985 ◽  
Author(s):  
Jeffrey I. Weitz ◽  
Iqbal H. Jaffer ◽  
James C. Fredenburgh
Keyword(s):  
Venous Thromboembolism ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Factor Xa ◽  
Prevention Of Recurrence ◽  
Active Cancer ◽  
Routine Coagulation ◽  
Inhibit Factor

The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment.

Sign in / Sign up

Export Citation Format

Share Document